BJ 001
Alternative Names: BJ-001Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator BJ Bioscience
- Class Anti-infectives; Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Infections
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC, Injection)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (SC, Injection)
- 27 Mar 2023 BJ Bioscience and Merck enters into an agreement for phase I trial in Solid tumors